A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer
Abstract
A method for high-throughput functional analysis identifies drug-insensitive EGFR mutations in tumors.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In preclinical studies, the L861Q mutation is resistant to first-generation TKIs, whereas it might be sensitive to afatinib or osimertinib.
“In preclinical studies, the L861Q mutation is resistant to fi rst-generation TKIs, whereas it might be sensitive to afatinib or osimertinib. 28-31”
From Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) (2020) · cites this paper as [31]
The citation lists haven’t been fetched yet
References 46 · Cited by 210
- Authors
- Kohsaka, S., Nagano, M., Ueno, T., Suehara, Y., Hayashi, T., Shimada, N., Takahashi, K., Suzuki, K., Takamochi, K., Takahashi, F., & Mano, H.
- Affiliations
- The University of Tokyo (JP)
- Juntendo University (JP)
- National Cancer Center Research Institute (JP)
- Corresponding author
- Kohsaka, Shinji
- Nagano, Masaaki
- Mano, Hiroyuki
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-11-15
- Volume
- 9
- Issue
- 416
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2769659311
- Cited by
- 210
- References
- 46
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 22 · 2023: 26 · 2022: 32 · 2021: 33 · 2020: 40 · 2019: 20 · 2018: 16 · 2017: 1
- FWCI
- 17.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (15H04964, 26461200, 16K15670, 15KK0353, 17K07250, 17K09669, 15K09230)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR, variants of uncertain significance, genetic variants, cancer, functional assessment, high-throughput screening, precision oncology, cancer genes
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Animals, Antineoplastic Agents, Cell Survival, Exons, Humans, Mutation, Quinazolines, 3T3 Cells, Drug Resistance, Neoplasm, Mice, HEK293 Cells, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
